tiprankstipranks
Mirum Pharmaceuticals (MX:MIRM)
NASDAQ:MIRM
Mexico Market
MIRM
Mirum Pharmaceuticals
RESEARCH TOOLSreports

Mirum Pharmaceuticals (MIRM) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

MIRM Analyst Ratings

Strong Buy
13Ratings
Strong Buy
13 Buy
0 Hold
0 Sell
Based on 13 analysts giving stock ratings to
Mirum
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

MIRM Stock 12 Month Forecast

Average Price Target

$2,570.20
▲(104.61% Upside)
Based on 13 Wall Street analysts offering 12 month price targets for Mirum Pharmaceuticals in the last 3 months. The average price target is $2,570.20 with a high forecast of $3,234.61 and a low forecast of $2,185.54. The average price target represents a 104.61% change from the last price of $1,256.12.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"947":"$947","1519":"$1,519","2091":"$2,091","2663":"$2,663","3235":"$3,235"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3234.6050293499998,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$3.23K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2570.19967197,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.57K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2185.54393875,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.19K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[947,1519,2091,2663,3235],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1256.12,1408.311156103846,1560.5023122076923,1712.6934683115383,1864.8846244153845,2017.0757805192306,2169.2669366230766,2321.4580927269226,2473.649248830769,2625.8404049346154,2778.0315610384614,2930.2227171423074,3082.4138732461533,{"y":3234.6050293499998,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1256.12,1357.20305169,1458.28610338,1559.36915507,1660.45220676,1761.5352584500001,1862.61831014,1963.70136183,2064.7844135200003,2165.86746521,2266.9505169000004,2368.03356859,2469.11662028,{"y":2570.19967197,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1256.12,1327.6141491346152,1399.1082982692308,1470.602447403846,1542.0965965384614,1613.590745673077,1685.0848948076923,1756.5790439423076,1828.073193076923,1899.5673422115385,1971.0614913461538,2042.5556404807694,2114.0497896153847,{"y":2185.54393875,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":948.54,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":948.54,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1256.12,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1256.12,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1256.12,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1256.12,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1256.12,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1256.12,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1256.12,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1256.12,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1256.12,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1256.12,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1256.12,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 43, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$3,235Average Price Target$2,570Lowest Price Target$2,186
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on MX:MIRM
Lisa Walter
RBC Capital
RBC Capital
$2,482.78→$2,587.68
Buy
106.01%
Upside
Reiterated
07/07/26
Mirum Pharmaceuticals price target raised to $148 from $142 at RBC CapitalMirum Pharmaceuticals price target raised to $148 from $142 at RBC Capital
J.P. Morgan Analyst forecast on MX:MIRM
Jessica Fye
J.P. Morgan
J.P. Morgan
$2,010.7→$2,185.54
Buy
73.99%
Upside
Reiterated
07/02/26
Mirum Pharmaceuticals price target raised to $125 from $115 at JPMorganMirum Pharmaceuticals price target raised to $125 from $115 at JPMorgan
Citizens JMP Analyst forecast on MX:MIRM
Jonathan Wolleben
Citizens JMP
Citizens JMP
$2,447.81→$2,552.72
Buy
103.22%
Upside
Reiterated
06/15/26
Mirum Pharmaceuticals price target raised to $146 from $140 at CitizensMirum Pharmaceuticals price target raised to $146 from $140 at Citizens
H.C. Wainwright Analyst forecast on MX:MIRM
Swayampakula Ramakanth
H.C. Wainwright
H.C. Wainwright
$3,234.61
Buy
157.51%
Upside
Reiterated
06/15/26
Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (NYSE: DGX), Celldex (NASDAQ: CLDX) and Mirum Pharmaceuticals (NASDAQ: MIRM)
Morgan Stanley Analyst forecast on MX:MIRM
Michael Ulz
Morgan Stanley
Morgan Stanley
$2,622.65
Buy
108.79%
Upside
Reiterated
06/15/26
Mirum Therapeutics: Strong FOP Data and Priority Review Support Buy Rating and Unchanged $150 Price Target
Citi Analyst forecast on MX:MIRM
Yigal Nochomovitz
Citi
Citi
$2,535.23
Buy
101.83%
Upside
Reiterated
06/14/26
Buy Rating Reiterated on Mirum Pharmaceuticals as Zilurgisertib Data De-Risk Pipeline; $145 Price Target Unchanged with ~46% Upside Potential
Wolfe Research Analyst forecast on MX:MIRM
Kalpit Patel
Wolfe Research
Wolfe Research
$2,535.23
Buy
101.83%
Upside
Initiated
05/19/26
Mirum Pharmaceuticals initiated with an Outperform at Wolfe ResearchMirum Pharmaceuticals initiated with an Outperform at Wolfe Research
Leerink Partners Analyst forecast on MX:MIRM
Mani Foroohar
Leerink Partners
Leerink Partners
$2,622.65→$2,692.59
Buy
114.36%
Upside
Reiterated
05/15/26
Leerink Partners Remains a Buy on Mirum Pharmaceuticals (MIRM)
Evercore ISI Analyst forecast on MX:MIRM
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
$2,360.39→$2,412.84
Buy
92.09%
Upside
Reiterated
05/07/26
Mirum Pharmaceuticals price target raised to $138 from $135 at Evercore ISIMirum Pharmaceuticals price target raised to $138 from $135 at Evercore ISI
TD Cowen Analyst forecast on MX:MIRM
Joseph Thome
TD Cowen
TD Cowen
$2,185.54→$2,535.23
Buy
101.83%
Upside
Assigned
05/07/26
Analysts Are Bullish on These Healthcare Stocks: InflaRx (IFRX), Mirum Pharmaceuticals (MIRM)
Raymond James Analyst forecast on MX:MIRM
Ryan Deschner
Raymond James
Raymond James
$2,867.43→$2,884.92
Buy
129.67%
Upside
Reiterated
05/07/26
Mirum Pharmaceuticals price target raised to $165 from $164 at Raymond JamesMirum Pharmaceuticals price target raised to $165 from $164 at Raymond James
Stifel Nicolaus Analyst forecast on MX:MIRM
James Condulis
Stifel Nicolaus
Stifel Nicolaus
$2,272.97→$2,377.87
Buy
89.30%
Upside
Reiterated
05/07/26
Stifel Nicolaus Sticks to Their Buy Rating for Mirum Pharmaceuticals (MIRM)
Robert W. Baird Analyst forecast on MX:MIRM
Brian Skorney
Robert W. Baird
Robert W. Baird
$1,958.25→$2,255.48
Buy
79.56%
Upside
Reiterated
05/07/26
Mirum Pharmaceuticals price target raised to $129 from $112 at BairdMirum Pharmaceuticals price target raised to $129 from $112 at Baird
Cantor Fitzgerald Analyst forecast on MX:MIRM
Joshua Schimmer
Cantor Fitzgerald
Cantor Fitzgerald
$2,447.81
Buy
94.87%
Upside
Reiterated
04/09/26
Cantor Fitzgerald Sticks to Their Buy Rating for Mirum Pharmaceuticals (MIRM)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on MX:MIRM
Lisa Walter
RBC Capital
RBC Capital
$2,482.78→$2,587.68
Buy
106.01%
Upside
Reiterated
07/07/26
Mirum Pharmaceuticals price target raised to $148 from $142 at RBC CapitalMirum Pharmaceuticals price target raised to $148 from $142 at RBC Capital
J.P. Morgan Analyst forecast on MX:MIRM
Jessica Fye
J.P. Morgan
J.P. Morgan
$2,010.7→$2,185.54
Buy
73.99%
Upside
Reiterated
07/02/26
Mirum Pharmaceuticals price target raised to $125 from $115 at JPMorganMirum Pharmaceuticals price target raised to $125 from $115 at JPMorgan
Citizens JMP Analyst forecast on MX:MIRM
Jonathan Wolleben
Citizens JMP
Citizens JMP
$2,447.81→$2,552.72
Buy
103.22%
Upside
Reiterated
06/15/26
Mirum Pharmaceuticals price target raised to $146 from $140 at CitizensMirum Pharmaceuticals price target raised to $146 from $140 at Citizens
H.C. Wainwright Analyst forecast on MX:MIRM
Swayampakula Ramakanth
H.C. Wainwright
H.C. Wainwright
$3,234.61
Buy
157.51%
Upside
Reiterated
06/15/26
Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (NYSE: DGX), Celldex (NASDAQ: CLDX) and Mirum Pharmaceuticals (NASDAQ: MIRM)
Morgan Stanley Analyst forecast on MX:MIRM
Michael Ulz
Morgan Stanley
Morgan Stanley
$2,622.65
Buy
108.79%
Upside
Reiterated
06/15/26
Mirum Therapeutics: Strong FOP Data and Priority Review Support Buy Rating and Unchanged $150 Price Target
Citi Analyst forecast on MX:MIRM
Yigal Nochomovitz
Citi
Citi
$2,535.23
Buy
101.83%
Upside
Reiterated
06/14/26
Buy Rating Reiterated on Mirum Pharmaceuticals as Zilurgisertib Data De-Risk Pipeline; $145 Price Target Unchanged with ~46% Upside Potential
Wolfe Research Analyst forecast on MX:MIRM
Kalpit Patel
Wolfe Research
Wolfe Research
$2,535.23
Buy
101.83%
Upside
Initiated
05/19/26
Mirum Pharmaceuticals initiated with an Outperform at Wolfe ResearchMirum Pharmaceuticals initiated with an Outperform at Wolfe Research
Leerink Partners Analyst forecast on MX:MIRM
Mani Foroohar
Leerink Partners
Leerink Partners
$2,622.65→$2,692.59
Buy
114.36%
Upside
Reiterated
05/15/26
Leerink Partners Remains a Buy on Mirum Pharmaceuticals (MIRM)
Evercore ISI Analyst forecast on MX:MIRM
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
$2,360.39→$2,412.84
Buy
92.09%
Upside
Reiterated
05/07/26
Mirum Pharmaceuticals price target raised to $138 from $135 at Evercore ISIMirum Pharmaceuticals price target raised to $138 from $135 at Evercore ISI
TD Cowen Analyst forecast on MX:MIRM
Joseph Thome
TD Cowen
TD Cowen
$2,185.54→$2,535.23
Buy
101.83%
Upside
Assigned
05/07/26
Analysts Are Bullish on These Healthcare Stocks: InflaRx (IFRX), Mirum Pharmaceuticals (MIRM)
Raymond James Analyst forecast on MX:MIRM
Ryan Deschner
Raymond James
Raymond James
$2,867.43→$2,884.92
Buy
129.67%
Upside
Reiterated
05/07/26
Mirum Pharmaceuticals price target raised to $165 from $164 at Raymond JamesMirum Pharmaceuticals price target raised to $165 from $164 at Raymond James
Stifel Nicolaus Analyst forecast on MX:MIRM
James Condulis
Stifel Nicolaus
Stifel Nicolaus
$2,272.97→$2,377.87
Buy
89.30%
Upside
Reiterated
05/07/26
Stifel Nicolaus Sticks to Their Buy Rating for Mirum Pharmaceuticals (MIRM)
Robert W. Baird Analyst forecast on MX:MIRM
Brian Skorney
Robert W. Baird
Robert W. Baird
$1,958.25→$2,255.48
Buy
79.56%
Upside
Reiterated
05/07/26
Mirum Pharmaceuticals price target raised to $129 from $112 at BairdMirum Pharmaceuticals price target raised to $129 from $112 at Baird
Cantor Fitzgerald Analyst forecast on MX:MIRM
Joshua Schimmer
Cantor Fitzgerald
Cantor Fitzgerald
$2,447.81
Buy
94.87%
Upside
Reiterated
04/09/26
Cantor Fitzgerald Sticks to Their Buy Rating for Mirum Pharmaceuticals (MIRM)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BBOTBridgeBio Oncology Therapeutics
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Mirum Pharmaceuticals

3 Months
Michael UlzMorgan Stanley
Success Rate
15/19 ratings generated profit
79%
Average Return
+15.07%
reiterated a buy rating last month
Copying Michael Ulz's trades and holding each position for 3 Months would result in 78.95% of your transactions generating a profit, with an average return of +15.07% per trade.
1 Year
Gavin Clark-GartnerEvercore ISI
Success Rate
16/16 ratings generated profit
100%
Average Return
+64.20%
reiterated a buy rating 3 months ago
Copying Gavin Clark-Gartner's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +64.20% per trade.
2 Years
Jonathan WollebenCitizens JMP
Success Rate
22/22 ratings generated profit
100%
Average Return
+146.16%
reiterated a buy rating last month
Copying Jonathan Wolleben's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +146.16% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MIRM Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
0
1
9
13
12
Buy
26
24
31
29
28
Hold
13
12
17
22
43
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
39
37
57
64
83
In the current month, MIRM has received 40 Buy Ratings, 43 Hold Ratings, and 0 Sell Ratings. MIRM average Analyst price target in the past 3 months is 2,570.20.
Each month's total comprises the sum of three months' worth of ratings.

MIRM Financial Forecast

MIRM Earnings Forecast

Next quarter’s earnings estimate for MIRM is -$12.69 with a range of -$25.63 to -$7.15. The previous quarter’s EPS was -$234.14. MIRM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 46.72% of the time in the same period. In the last calendar year MIRM has Performed in-line its overall industry.
Next quarter’s earnings estimate for MIRM is -$12.69 with a range of -$25.63 to -$7.15. The previous quarter’s EPS was -$234.14. MIRM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 46.72% of the time in the same period. In the last calendar year MIRM has Performed in-line its overall industry.

MIRM Sales Forecast

Next quarter’s sales forecast for MIRM is $2.89B with a range of $2.79B to $3.02B. The previous quarter’s sales results were $2.79B. MIRM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 30.94% of the time in the same period. In the last calendar year MIRM has Performed in-line its overall industry.
Next quarter’s sales forecast for MIRM is $2.89B with a range of $2.79B to $3.02B. The previous quarter’s sales results were $2.79B. MIRM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 30.94% of the time in the same period. In the last calendar year MIRM has Performed in-line its overall industry.

MIRM Stock Forecast FAQ

What is MX:MIRM’s average 12-month price target, according to analysts?
Based on analyst ratings, Mirum Pharmaceuticals’s 12-month average price target is 2,570.20.
    What is MX:MIRM’s upside potential, based on the analysts’ average price target?
    Mirum Pharmaceuticals has 104.61% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Mirum Pharmaceuticals a Buy, Sell or Hold?
          Mirum Pharmaceuticals has a consensus rating of Strong Buy, which is based on 13 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Mirum Pharmaceuticals’s share price target?
            The average share price target for Mirum Pharmaceuticals is 2,570.20. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $3,234.61 ,and the lowest forecast is $2,185.54. The average share price target represents 104.61% Increase from the current price of $1,256.12.
              What do analysts say about Mirum Pharmaceuticals?
              Mirum Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of Mirum Pharmaceuticals?
                To buy shares of MX:MIRM, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.